Kura Oncology (KURA) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Kura Oncology (KURA) over the past year, gaining 14.2% versus a loss of 38.1%. Over five years, KURA leads with a -50.7% price change compared with -67.7% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($681.2 million vs $634.9 million), about 1.1 times the size.
Lexicon Pharmaceuticals converts more of its revenue into profit, with a net margin of -101.1% versus -412.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | LXRX |
|---|---|---|
| Share price | $6.91 | $1.53 |
| Market cap | $634.88M | $681.21M |
| 1-day change | -5.99% | -8.38% |
| YTD return | -33.49% | +33.04% |
| 1-year return | -38.14% | +14.18% |
| 5-year return | -50.66% | -67.72% |
| EPS (TTM) | $-3.30 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.48M | $49.80M |
| Revenue growth (YoY) | +25.24% | +60.24% |
| Net income (latest FY) | $-278.67M | $-50.34M |
| Gross margin | — | 99.45% |
| Operating margin | -449.94% | -98.21% |
| Net margin | -412.95% | -101.08% |
| 52-week high | $13.90 | $2.68 |
| 52-week low | $6.75 | $1.10 |
| Distance from 52-week high | -50.29% | -42.91% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +357.60% | +195.42% |
| Average volume | 2.10M | 2.56M |
| Shares outstanding | 91.88M | 445.23M |
| Employees | 260 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed KURA by 52.3 percentage points over the past year.
- Lexicon Pharmaceuticals is more profitable, keeping -101.1 cents of every revenue dollar as net income versus -412.9 cents for Kura Oncology.
- Lexicon Pharmaceuticals grew revenue faster in its latest fiscal year (+60.24% vs +25.24%).
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
KURA vs LXRX FAQ
Which is bigger, Kura Oncology or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $681.21M compared with $634.88M for Kura Oncology (KURA).
Which stock has performed better over the past year, KURA or LXRX?
LXRX returned +14.18% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.